Fruquintinib Elunate, Sulanda

What it is

Fruquintinib is an oral multi-kinase inhibitor approved for the treatment of metastatic colorectal cancer in patients who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy. It serves as a third-line or later treatment option for advanced CRC patients whose tumors have progressed on standard therapies. The drug has demonstrated efficacy in microsatellite stable (MSS) colorectal cancer and is used in combination with other agents like raltitrexed in clinical practice.

How it works

Fruquintinib selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are key regulators of tumor angiogenesis and vascular permeability. By blocking these receptors, the drug disrupts the formation of new blood vessels that tumors require for growth and metastasis. This anti-angiogenic mechanism leads to tumor vessel normalization and reduced tumor blood supply, ultimately inhibiting cancer cell proliferation and survival.

Molecular targets

Common side effects

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.